ArticleDigestive diseases and sciences2026
Rates of Aerodigestive Cancer After Positive mt-sDNA and Colonoscopy Without Advanced Colorectal Neoplasia in Patients with a Prior Cancer History.
Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsMultitarget stool DNA (mt-sDNA) testing is widely used for colorectal cancer (CRC) screening, however the clinical implications of a positive mt-sDNA results with a subsequent negative colonoscopy remain unclear especially in patients with a history of non-CRC malignancy. This study aimed to characterize the long-term incidence of new or recurrent malignancy in these patients.
methodsThis retrospective, single-center study was conducted at Memorial Sloan Kettering Cancer Center between 2014 and 2024. Patients included had a history of non-CRC malignancy, a positive mt-sDNA result, and a subsequent colonoscopy without advanced colorectal neoplasia. Exclusion criteria included prior CRC, inadequate follow-up, or ineligibility for mt-sDNA testing. The primary outcome was the incidence of new or recurrent cancer, classified by location and organ system. Aerodigestive tract involvement was defined to include the lungs, oropharynx, esophagus, stomach, liver, pancreas, bowel, and parotid gland. MSK-IMPACT® tumor sequencing was reviewed when available.
resultsSixty-five patients met inclusion criteria. With a median follow-up of 28 months, 14 patients (22%) developed new or recurrent disease; 13 of these (93%) involved the aerodigestive tract. Malignancy-related events included primary gastric, lung, and hypopharyngeal cancers, as well as recurrent or metastatic disease involving aerodigestive and gastrointestinal organs. There were no significant differences in demographics or colonoscopy findings between groups. However, patients who remained disease-free were more likely to have never smoked (63% vs. 23%, p = 0.03). Of six patients with MSK-IMPACT® data, one had a KRAS mutation targeted by mt-sDNA.
conclusionIn this cohort, approximately one in five patients were subsequently diagnosed with a new primary malignancy or recurrent disease; these findings require further study, do not support changes in clinical surveillance, and highlight the need for careful discussion when ordering mt-sDNA testing in patients with prior non-CRC.
Indexed as
Identifiers
42836935What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.